Aurobindo receives FDA OK for 2 generics

Aurobindo has received clearance from the Food and Drug Administration for two generics.

The company has received FDA permission for ertugliflozin tablets, 5 mg and 15 mg, which is the generic of Merck's Steglatro.

Ertugliflozin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus.

[Read more: Aurobindo receives FDA OK for generic Renagel]

Ertugliflozin tablets have a market value of roughly $269.7 million for the 12 months ending May 2023, per IQVIA.

[Read more: Aurobindo gets FDA nod for 3 generics]

Aurobindo also has received the FDA's nod for apremilast tablets, 10 mg, 20 mg and 30 mg, which is the generic of Amgen's Otezla.

Apremilast tablets are indicated for the treatment of adult patients with active psoriatic arthritis; and for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Apremilast tablets have a market value of roughly $3.6 billion for the 12 months ending May 2023, per IQVIA.